 A live audio webcast of the fireside chat and presentation will be available in the Investors section of Harpoon Therapeutics website at Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the bodys immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct TriTAC platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. 